Literature DB >> 20481602

Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen.

Zhongliang Xu1, Yiying Li, Qi Xiang, Zhong Pei, Xilin Liu, Bingtai Lu, Ling Chen, Guanlei Wang, Jiyan Pang, Yongcheng Lin.   

Abstract

A novel series of xyloketal derivatives (1-21) were designed and prepared. The majority of the compounds demonstrated vasorelaxation action on 60 mM KCl-induced contractions rat isolated aortic rings in a concentration-dependent manner, and the action is mediated by both endothelium-independent and endothelium-dependent mechanisms. Compounds 9, 12, 13, 14, 15, and 19 showed higher vasorelaxation activities comparing with the lead compound 3. In addition, these derivatives had potential protective action against oxLDL-induced endothelial oxidative injury and enhanced NO production in HUVECs without toxic effects. The NO release was completely inhibited by eNOS inhibitor L-NAME. Furthermore, 3 significantly promoted the angiogenesis in zebrafish in a concentration-dependent manner at 0.1, 1, and 10 muM. Compounds 9, 12, 14, 16, 20, and 21 exhibited stronger angiogenic activities than 3. Therefore, xyloketal derivatives are unique compounds with multiple pharmacological properties and may have potential implications in the treatment of cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20481602     DOI: 10.1021/jm1001502

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Xyloketal B exerts antihypertensive effect in renovascular hypertensive rats via the NO-sGC-cGMP pathway and calcium signaling.

Authors:  Li-Yan Zhao; Jie Li; Xiong-Qing Huang; Guo-Hao Wang; Xiao-Fei Lv; Wei-Feng Meng; Wen-Liang Chen; Ji-Yan Pang; Yong-Cheng Lin; Hong-Shuo Sun; Guan-Lei Wang; Yao-Min Du
Journal:  Acta Pharmacol Sin       Date:  2018-03-29       Impact factor: 6.150

2.  15 years of zebrafish chemical screening.

Authors:  Andrew J Rennekamp; Randall T Peterson
Journal:  Curr Opin Chem Biol       Date:  2014-11-15       Impact factor: 8.822

Review 3.  Chemical screening in zebrafish for novel biological and therapeutic discovery.

Authors:  D S Wiley; S E Redfield; L I Zon
Journal:  Methods Cell Biol       Date:  2016-12-29       Impact factor: 1.441

4.  Marine cyclotripeptide X-13 promotes angiogenesis in zebrafish and human endothelial cells via PI3K/Akt/eNOS signaling pathways.

Authors:  Xi-Lin Lu; Zhong-Liang Xu; Xiao-Li Yao; Feng-Juan Su; Cheng-Hui Ye; Jing Li; Yong-Cheng Lin; Guang-Lei Wang; Jin-Sheng Zeng; Ru-Xun Huang; Jing-Song Ou; Hong-Shuo Sun; Li-Ping Wang; Ji-Yan Pang; Zhong Pei
Journal:  Mar Drugs       Date:  2012-06-07       Impact factor: 6.085

5.  Xyloketal B attenuates atherosclerotic plaque formation and endothelial dysfunction in apolipoprotein e deficient mice.

Authors:  Li-Yan Zhao; Jie Li; Feng Yuan; Mei Li; Quan Zhang; Yun-Ying Huang; Ji-Yan Pang; Bin Zhang; Fang-Yun Sun; Hong-Shuo Sun; Qian Li; Lu Cao; Yu Xie; Yong-Cheng Lin; Jie Liu; Hong-Mei Tan; Guan-Lei Wang
Journal:  Mar Drugs       Date:  2015-04-14       Impact factor: 5.118

6.  Synthesis and neuroprotective action of xyloketal derivatives in Parkinson's disease models.

Authors:  Shichang Li; Cunzhou Shen; Wenyuan Guo; Xuefei Zhang; Shixin Liu; Fengyin Liang; Zhongliang Xu; Zhong Pei; Huacan Song; Liqin Qiu; Yongcheng Lin; Jiyan Pang
Journal:  Mar Drugs       Date:  2013-12-18       Impact factor: 5.118

7.  Design and synthesis of novel xyloketal derivatives and their protective activities against H2O2-induced HUVEC injury.

Authors:  Shixin Liu; Rong Luo; Qi Xiang; Xianfang Xu; Liqin Qiu; Jiyan Pang
Journal:  Mar Drugs       Date:  2015-02-12       Impact factor: 5.118

8.  Marine compound xyloketal B reduces neonatal hypoxic-ischemic brain injury.

Authors:  Ai-Jiao Xiao; Wenliang Chen; Baofeng Xu; Rui Liu; Ekaterina Turlova; Andrew Barszczyk; Christopher Lf Sun; Ling Liu; Marielle Deurloo; Guan-Lei Wang; Zhong-Ping Feng; Hong-Shuo Sun
Journal:  Mar Drugs       Date:  2014-12-24       Impact factor: 5.118

9.  Xyloketal B exhibits its antioxidant activity through induction of HO-1 in vascular endothelial cells and zebrafish.

Authors:  Zhen-Xing Li; Jian-Wen Chen; Feng Yuan; Yun-Ying Huang; Li-Yan Zhao; Jie Li; Huan-Xing Su; Jie Liu; Ji-Yan Pang; Yong-Cheng Lin; Xi-Lin Lu; Zhong Pei; Guan-Lei Wang; Yong-Yuan Guan
Journal:  Mar Drugs       Date:  2013-02-18       Impact factor: 5.118

10.  Xyloketal B suppresses glioblastoma cell proliferation and migration in vitro through inhibiting TRPM7-regulated PI3K/Akt and MEK/ERK signaling pathways.

Authors:  Wen-Liang Chen; Ekaterina Turlova; Christopher L F Sun; Ji-Sun Kim; Sammen Huang; Xiao Zhong; Yong-Yuan Guan; Guan-Lei Wang; James T Rutka; Zhong-Ping Feng; Hong-Shuo Sun
Journal:  Mar Drugs       Date:  2015-04-22       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.